A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer

NCT02138422 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic Colorectal Cancer
Advanced Colorectal Cancer
Colorectal Cancer With Cachexia

Interventions

BIOLOGICAL: Xilonix
BIOLOGICAL: Placebo

Sponsor

Janssen Research & Development, LLC